Verigraft is active in the field of regenerative medicine by developing personalized human tissues for transplantation. VERIGRAFT was granted € 2.2M from the SME Instrument HORIZON 2020, phase 2.
“The SME Instrument funding represents an important element on our way to the next level of development and we are very proud to have been promoted to the SME Champions league. The VERIGRAFT team is very thankful for this reward of our rock-solid commitment and we are highly motivated to make this project a great success. This funding will facilitate our high ambitions to develop novel products that can help millions of patients with today incurable diseases.”
Dr. Petter Björquist, CEO, VERIGRAFT